The effects of HIV Tat DNA on regulating the immune response of HIV DNA vaccine in mice

Virology Journal

Volumn 10, Issue , 2013, Pages

  Liu, Ye ^a   Li, Fusheng ^c   Qi, Zhi ^b   Hao, Yanling ^b   Hong, Kunxue ^b   Liu, Yong ^b   Cong, Yulong ^a   Shao, Yiming ^b  

^a General Hospital of Chinese P L A   (China)

^b CHINESE CENTER FOR DISEASE CONTROL AND PREVENTION   (China)

^c USA   (United States)

Author keywords

HIV DNA vaccine; IgG subclass; T cell response; Tat expression plasmid; Th polarization

Indexed keywords

DNA VACCINE; GAG PROTEIN; GAMMA INTERFERON; HUMAN IMMUNODEFICIENCY VIRUS VACCINE; IMMUNOGLOBULIN G1; IMMUNOGLOBULIN G2A; IMMUNOGLOBULIN G3; PLASMID VECTOR; POL PROTEIN; TRANSACTIVATOR PROTEIN; VIRUS ANTIBODY; VIRUS DNA; VIRUS ENVELOPE PROTEIN;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANTIBODY RESPONSE; ANTIBODY TITER; ANTIGEN EXPRESSION; ANTIGEN SPECIFICITY; ARTICLE; CELLULAR IMMUNITY; CONTROLLED STUDY; CYTOKINE RESPONSE; DNA IMMUNIZATION; DRUG POTENTIATION; ENZYME LINKED IMMUNOSORBENT ASSAY; ENZYME LINKED IMMUNOSPOT ASSAY; FEMALE; GENETIC CODE; HUMAN IMMUNODEFICIENCY VIRUS 1; HUMAN IMMUNODEFICIENCY VIRUS 1 INFECTION; IMMUNOREGULATION; IMMUNOSTIMULATION; MOUSE; NONHUMAN; PROTEIN EXPRESSION; VIRUS IMMUNITY; WESTERN BLOTTING;

MUS;

AIDS VACCINES; ANIMALS; ENV GENE PRODUCTS, HUMAN IMMUNODEFICIENCY VIRUS; FEMALE; GAG GENE PRODUCTS, HUMAN IMMUNODEFICIENCY VIRUS; INTERFERON-GAMMA; MICE; POL GENE PRODUCTS, HUMAN IMMUNODEFICIENCY VIRUS; TAT GENE PRODUCTS, HUMAN IMMUNODEFICIENCY VIRUS; VACCINATION; VACCINES, DNA;

EID: 84884862089     PISSN: None     EISSN: 1743422X     Source Type: Journal    
DOI: 10.1186/1743-422X-10-297     Document Type: Article

References (55)

1. Vaccinology: past achievements, present roadblocks and future promises. Francis EA, Vaccine 2003 21 593 595 10.1016/S0264-410X(02)00702-8 12531323 (Pubitemid 36091965)
2. Direct gene transfer into mouse muscle in vivo. Wolff JA, Malone RW, Williams P, Chong W, Acsadi G, Jani A, Felgner PL, Science 1990 247 1465 1468 10.1126/science.1690918 1690918
3. Long-term persistence of plasmid DNA and foreign gene expression in mouse muscle. Wolff JA, Ludtke JJ, Acsadi G, Williams P, Jani A, Hum Mol Genet 1992 6 363 369
4. Current progress of DNA vaccine studies in humans. Lu S, Wang S, Grimes-Serrano JM, Expert Rev Vaccines 2008 7 175 191 10.1586/14760584.7.2.175 18324888 (Pubitemid 351357954)
5. Immunogenicity, safety, biodistribution and persistence of ADVAX, a prophylactic DNA vaccine for HIV-1, delivered by in vivo electroporation. Dolter KE, Evans CF, Ellefsen B, Song J, Boente-Carrera M, Vittorino R, Rosenberg TJ, Hannaman D, Vasan S, Vaccine 2011 29 795 803 10.1016/j.vaccine.2010.11.011 21094270
6. Phase 1 safety and immunogenicity evaluation of ADVAX, a multigenic, DNA-based clade C/B' HIV-1 candidate vaccine. Vasan S, Schlesinger SJ, Huang Y, Hurley A, Lombardo A, Chen Z, Than S, Adesanya P, Bunce C, Boaz M, Boyle R, Sayeed E, Clark L, Dugin D, Schmidt C, Song Y, Seamons L, Dally L, Ho M, Smith C, Markowitz M, Cox J, Gill DK, Gilmour J, Keefer MC, Fast P, Ho DD, PLoS One 2010 5 8617 10.1371/journal.pone.0008617
7. DNA vaccines: immunology, application and optimization. Gurunathan S, Klinman DM, Seder RA, Annu Rev Immunol 2000 18 927 974 10.1146/annurev.immunol. 18.1.927 10837079 (Pubitemid 30365401)
8. DNA vaccines: protective immunizations by parenteral, mucosal, and gene-gun inoculations. Fynan EF, Webster RG, Fuller DH, Haynes JR, Santoro JC, Robinson HL, Proc Natl Acad Sci U S A 1993 90 11478 11482 10.1073/pnas.90.24. 11478 8265577 (Pubitemid 24008662)
9. Attenuated and wild-type HIV-1 infections and long terminal repeat-mediated gene expression from plasmids delivered by gene gun to human skin ex vivo and macaques in vivo. Kent SJ, Cameron PU, Reece JC, Thompson PR, Purcell DF, Virology 2001 287 71 78 10.1006/viro.2001.1019 11504543 (Pubitemid 32778240)
10. Cytokine-adjuvanted HIV-DNA vaccination strategies. Lori F, Weiner DB, Calarota SA, Kelly LM, Lisziewicz J, Springer Semin Immunopathol 2006 28 231 238 10.1007/s00281-006-0047-y 17053912 (Pubitemid 44764279)
11. Effect of plasmid DNA vaccine design and in vivo electroporation on the resulting vaccine-specific immune responses in rhesus macaques. Luckay A, Sidhu MK, Kjeken R, Megati S, Chong SY, Roopchand V, Garcia-Hand D, Abdullah R, Braun R, Montefiori DC, Rosati M, Felber BK, Pavlakis GN, Mathiesen I, Israel ZR, Eldridge JH, Egan MA, J Virol 2007 81 5257 5269 10.1128/JVI.00055-07 17329330 (Pubitemid 46744435)
12. Enhancing DNA vaccine potency by modifying the properties of antigen-presenting cells. Tsen SW, Paik AH, Hung CF, Wu TC, Expert Rev Vaccines 2007 6 227 239 10.1586/14760584.6.2.227 17408372 (Pubitemid 46607458)
13. Relative contributions of codon usage, promoter efficiency and leader sequence to the antigen expression and immunogenicity of HIV-1 Env DNA vaccine. Wang S, Farfan-Arribas DJ, Shen S, Chou TH, Hirsch A, He F, Lu S, Vaccine 2006 24 4531 4540 10.1016/j.vaccine.2005.08.023 16140431 (Pubitemid 43776774)
14. Single DNA immunization in combination with electroporation prolongs the primary immune response and maintains immune memory for six months. Griebel PA, Babiuk LA, van van Drunen Littel-van den Hurk S, Tsang C, Vaccine 2007 25 5485 5494 10.1016/j.vaccine.2007.03.009 17408815 (Pubitemid 47039264)
15. Regulation of cellular gene expression and function by the human immunodeficiency virus type 1 Tat protein. Chang HK, Gallo RC, Ensoli B, J Biomed Sci 1995 2 189 202 10.1007/BF02253380 11725056
16. The Tat protein of human immunodeficiency virus type 1, a growth factor for AIDS-Kaposi sarcoma and cytokine-activated vascular cells, induces adhesion of the same cell types by using integrin receptors recognizing the RGD sequence. Barillari G, Gendelman R, Gallo RC, Ensoli B, Proc Natl Acad Sci U S A 1993 90 7941 7945 10.1073/pnas.90.17.7941 7690138 (Pubitemid 23260830)
17. Candidate HIV-1 Tat vaccine development: from basic science to clinical trials. Ensoli B, Fiorelli V, Ensoli F, Cafaro A, Titti F, Butto S, Monini P, Magnani M, Caputo A, Garaci E, AIDS 2006 20 2245 2261 10.1097/QAD. 0b013e3280112cd1 17117011 (Pubitemid 44789527)
18. Identification of human immunodeficiency virus type 1 subtype C Gag-, Tat-, Rev-, and Nef-specific elispot-based cytotoxic T-lymphocyte responses for AIDS vaccine design. Novitsky V, Rybak N, McLane MF, Gilbert P, Chigwedere P, Klein I, Gaolekwe S, Chang SY, Peter T, Thior I, Ndung'u T, Vannberg F, Foley BT, Marlink R, Lee TH, Essex M, J Virol 2001 75 9210 9228 10.1128/JVI.75.19. 9210-9228.2001 11533184 (Pubitemid 32851925)
19. HIV-1 Tat addresses dendritic cells to induce a predominant Th1-type adaptive immune response that appears prevalent in the asymptomatic stage of infection. Fanales-Belasio E, Moretti S, Fiorelli V, Tripiciano A, Pavone-Cossut MR, Scoglio A, Collacchi B, Nappi F, Macchia I, Bellino S, Francavilla V, Caputo A, Barillari G, Magnani M, Laguardia ME, Cafaro A, Titti F, Monini P, Ensoli F, Ensoli B, J Immunol 2009 182 2888 2897 10.4049/jimmunol.0711406 19234184
20. Native HIV-1 Tat protein targets monocyte-derived dendritic cells and enhances their maturation, function, and antigen-specific T cell responses. Fanales-Belasio E, Moretti S, Nappi F, Barillari G, Micheletti F, Cafaro A, Ensoli B, J Immunol 2002 168 197 206 11751963 (Pubitemid 34014119)
21. HIV-1 Tat Protein Modulates the Generation of Cytotoxic T Cell Epitopes by Modifying Proteasome Composition and Enzymatic Activity. Gavioli R, Gallerani E, Fortini C, Fabris M, Bottoni A, Canella A, Bonaccorsi A, Marastoni M, Micheletti F, Cafaro A, Rimessi P, Caputo A, Ensoli B, J Immunol 2004 173 3838 3843 15356131 (Pubitemid 39280746)
22. Transfer of the ability of HIV-1 Tat to raise an adjuvant-free humoral immune response to unrelated antigens. Gadzinski A, Matz D, Favre E, Léonetti M, Vaccine 2012 30 2859 2868 10.1016/j.vaccine.2012.02.042 22386747
23. B-CELL STIMULATORY FACTOR-l / INTERLEUKIN4. William EP, Junichi O, Ann Rev lmmunol 1987 5 429 459 10.1146/annurev.iy.05.040187.002241
24. Role of T cells in the B-cell response: glutaraldehyde-fixed T-helper hybridoma cells synergize with the lymphokine IL-4 to induce B-cell activation and proliferation. Kubota E, Mckenzie DT, Dutton RW, Swain SL, Immunology 1991 72 40 47 1825482
25. Alternative activation of macrophages. Gordon S, Nature review immunology 2003 3 23 35 (Pubitemid 37328697)
26. Adjuvant guided polarization of the immune humoral response against a protective multicomponent antigenic protein (Q) from Leishmania infantum. A CpG + Q mix protects Balb/c mice from infection. Parody N, Soto M, Requena JM, Alonso C, Parasite Immunol 2004 26 283 293 10.1111/j.0141-9838.2004.00711.x 15541032 (Pubitemid 39576329)
27. Systems Analysis of MVA-C Induced Immune Response Reveals Its Significance as a Vaccine Candidate against HIV/AIDS of Clade C. Carmen Elena Gomez B, Beatriz P, Victoria J, Abdelali F-M, Khader G, Elias Haddad K, Esther Quakkerlaar D, Julie D, Alexandre H, Thierry R, Thomas D, Sekaly RP, Melief CJM, Thierry C, Federica S, Antonio L, Ralf W, Giuseppe P, Mariano E, PlosOne 2012 7 35485 10.1371/journal.pone.0035485
28. Vaccination with Leishmania histone H1-pulsed dendritic cells confers protection in murine visceral leishmaniasis. Maria A, Despina S, Ketty S, Evdokia K, Vaccine 2012 30 5086- 5093 22704924
29. The molecular biology of HIV latency: breaking and restoring the Tat-dependent transcriptional circuit. Karn J, Curr Opin HIV AIDS 2011 6 4 11 10.1097/COH.0b013e328340ffbb 21242887
30. Therapeutic Immunization with HIV-1 Tat Reduces Immune Activation and Loss of Regulatory T-Cells and Improves Immune Function in Subjects on HAART. Barbara E, Stefania B, Antonella T, Olimpia L, Vittorio F, Simone M, Aurelio C, Orietta P, Giovanni P, Arianna S, Angela A, Cristina A, Maria Ruiz Alvarez J, Massimo C, Donato S, Cristina I, Roberto E, Cristina M, Florio G, Laura S, Guido P, Alessandra L, Gioacchino A, Nicoletta L, Fabrizio S, Vito Mercurio S, Adriano L, Giuseppe T, Raffaele V, Francesco M, et al. PLOS ONE 2010 5 13540 10.1371/journal.pone.0013540
31. Contribution of Nonneutralizing Vaccine-Elicited Antibody Activities to Improved Protective Efficacy in Rhesus Macaques Immunized with Tat/Env Compared with Multigenic Vaccines. Florese RH, Thorsten D, Peng X, LaRene K, Kay L, Ebonita Summers L, David V, Aurelio C, Barbara E, Marjorie R-G, J Immunol 2009 182 3718 3727 10.4049/jimmunol.0803115 19265150
32. HIV-1 Tat Raises an Adjuvant-free Humoral Immune Response Controlled by Its Core Region and Its Ability to Form Cysteine-mediated Oligomers. Jongrak K, Alain Lecoq GM, Robert T, Evelyne L, Pascal D, Claude V, Andre M, Michel L, The Journal of biological chemistry 2006 281 6 3105 3115 16321975
33. Vaccination with TAT-Antigen Fusion Protein Induces Protective, CD8 T Cell-Mediated Immunity Against Leishmania Major. Katharina K, Sven B, Florian B, Yayoi T, Naotaka S, von Stebut MCUE, J Investig Dermatol 2010 130 2602 2610 10.1038/jid.2010.171 20574442
34. A Replication-Competent Adenovirus-Human Immunodeficiency Virus (Ad-HIV) tat and Ad-HIV env Priming/Tat and Envelope Protein Boosting Regimen Elicits Enhanced Protective Efficacy against Simian/Human Immunodeficiency Virus SHIV89.6P Challenge in Rhesus Macaques. Thorsten D, Ruth Florese H, Heath MJ, Kay L, Irene K, Kalyanaraman VS, Eun ML, Ranajit P, David V, Richard G, Jean Patterson L, Birgit K-S, Adam B, Dilani D, David Montefiori C, Norman Letvin L, Aurelio C, Barbara E, Marjorie R-G, Journal of virology 2007 81 3414 3427 10.1128/JVI.02453-06 17229693 (Pubitemid 46456650)
35. A combination HIV vaccine based on Tat and Env proteins was immunogenic and protected macaques from mucosal SHIV challenge in a pilot study. Vaccine 2011, 29:2918-2932.41. Rodriguez F, Zhang J, Whitton JL: DNA immunization: ubiquitination of a viral protein enhances cytotoxic T-lymphocyte induction and antiviral protection but abrogates antibody induction. Flavia F, Maria Teresa M, Ilaria S, Leonardo S, Erika O, Stefania F, Maria Rosaria P-C, Sonia M, Roberto B, Barbara C, Srivastava IK, Fausto T, Aurelio C, Barnett SW, Barbara E, J Virol 1997 71 8497 8503 9343207
36. Ubiquitin-fused and/or multiple early genes from cottontail rabbit papillomavirus as DNA vaccines. Leachman SA, Shylankevich M, Slade MD, Levine D, Sundaram RK, Xiao W, Bryan M, Zelterman D, Tiegelaar RE, Brandsma JL, J Virol 2002 76 7616 7624 10.1128/JVI.76.15.7616-7624.2002 12097575 (Pubitemid 34760985)
37. The ubiquitin-proteasome system plays essential roles in presenting an 8-mer CTL epitope expressed in APC to corresponding CD8+ T cells. Duan X, Hisaeda H, Shen J, Tu L, Imai T, Chou B, Murata S, Chiba T, Tanaka K, Fehling HJ, Koga T, Sueishi K, Himeno K, Int Immunol 2006 18 679 687 16569681 (Pubitemid 43779058)
38. Marjorie Robert-GuroffEnhanced cellular immunity to SIV Gag following co-administration of adenoviruses encoding wild-type or mutant HIV Tat and SIV Gag. Jun Z, Rebecca V, Bo P, Alberta D-W, Kalyanaraman VS, Gregory Alvord W, Kris A, Daniela B, Stefano B, Aurelio C, Barbara E, Virology 2005 342 1 12 10.1016/j.virol.2005.07.016 16109434 (Pubitemid 41531981)
39. The Tat protein broadens T cell responses directed to the HIV-1 antigens Gag and Env: Implications for the design of new vaccination strategies against AIDS. Riccardo G, Silvia C, Arianna C, Rebecca V, Eleonora G, Francesca G, Cinzia F, Egidio Brocca C, Chiara T, Aurelio C, Indresh S, Susan B, Antonella C, Barbara E, Vaccine 2008 26 727 737 10.1016/j.vaccine.2007.11.040 18096278
40. Intracellular HIV-1 Tat protein represses constitutive LMP2 transcription increasing proteasome activity by interfering with the binding of IRF-1 to STAT1. Remoli AL, Giulia M, Edvige P, Eleonora G, Ramona I, Filomena N, Aurelio C, Barbara E, Riccardo G, Angela B, Biochem J 2006 396 371 380 10.1042/BJ20051570 16512786 (Pubitemid 43837253)
41. Identification of HIV-1 specific T lymphocyte responses in highly exposed persistently seronegative Chinese. Liu HW, Hong KX, Ma J, Yuan L, Liu S, Chen JP, Zhang YZ, Ruan YH, Xu JQ, Shao YM, Chin Med J (Engl) 2006 119 1616 1621 (Pubitemid 44575622)
42. The delivery of HBcAg via Tat-PTD enhances specific immune response and inhibits Hepatitis B virus replication in transgenic mice. Chen X, Lai J, Pan Q, Tang Z, Yu Y, Zang G, Vaccine 2010 28 3913 3919 10.1016/j.vaccine.2010.03.070 20394723
43. HIV-1 Tat suppresses gp120-specific T cell response in IL-10-dependent manner. Gupta S, Boppana R, Mishra GC, Saha B, Mitra D, J Immunol 2008 180 79 88 18097007
44. Qualitative T-Helper Responses to Multiple Viral Antigens Correlate with Vaccine-Induced Immunity to Simian / Human Immunode fi ciency Virus Infection. Mooij P, Nieuwenhuis IG, Knoop CJ, Doms RW, Willy Bogers MJM, Peter ten Haaft JF, Niphuis H, Koornstra W, Bieler K, Kostler J, Morein B, Cafaro A, Ensoli B, Ralf Wagner E, Jonathan Heeney: L, J Virol 2004 78 3333 3342 10.1128/JVI.78.7.3333-3342.2004 15016855 (Pubitemid 38568274)
45. Restricted IgG subclass responses to HTLV-III/LAV and to cytomegalovirus in patients with AIDS and lymphadenopathy syndrome. Sundqvist VA, Linde A, Kurth R, Werner A, Helm EB, Popovic M, Gallo RC, Wahren B, J Infect Dis 1986 153 970 973 10.1093/infdis/153.5.970 3009638 (Pubitemid 16114876)
46. HIV type 1-specific IgG2 antibodies: markers of helper T cell type 1 response and prognostic marker of long-term nonprogression. Ngo-Giang-Huong N, Candotti D, Goubar A, Autran B, Maynart M, Sicard D, Clauvel JP, Agut H, Costagliola D, Rouzioux C, AIDS Res Hum Retroviruses 2001 17 1435 1446 10.1089/088922201753197105 11679156 (Pubitemid 33042811)
47. HIV-1 Tat modulates T-bet expression and induces Th1 type of immune response. Kulkarni A, Ravi DS, Singh K, Rampalli S, Parekh V, Mitra D, Chattopadhyay S, Biochem Biophys Res Commun 2005 329 706 712 10.1016/j.bbrc.2005.02.042 15737643 (Pubitemid 40320463)
48. Biosafety of DNA vaccines: New generation of DNA vectors and current knowledge on the fate of plasmids after injection. Faurez F, Dory D, Le-Moigne V, Gravier R, Jestin A, Vaccine 2010 28 3888 3895 10.1016/j.vaccine.2010.03.040 20371391
49. Cynomolgus macaques immunized with two HIV-1 Tat stabilized proteins raise strong and long-lasting immune responses with a pattern of Th1/Th2 response differing from that in mice. Turbant S, Martinon F, Moine G, Le-Grand R, Léonetti M, Vaccine 2009 27 5349 5356 10.1016/j.vaccine.2009.06.083 19607953
50. Effects of adjuvants on IgG subclasses elicited by virus-like Particles. Maria Luisa V, Maria T, Maria Lina T, Buonaguro FM, Luigi B, J Transl Med 2012 10 4 10.1186/1479-5876-10-4 22221900
51. Effect of intron A from human cytomegalovirus (Towne) immediate-early gene on heterologous expression in mammalian cells. Chapman BS, Thayer RM, Vincent KA, Haigwood NL, Nucleic Acids Res 1991 19 3979 3986 10.1093/nar/19.14.3979 1650459 (Pubitemid 21912770)
52. Human CMV immediate-early enhancer: a useful tool to enhance cell-type-specific expression from lentiviral vectors. Gruh I, Wunderlich S, Winkler M, Schwanke K, Heinke J, Blomer U, Ruhparwar A, Rohde B, Li RK, Haverich A, Martin U, J Gene Med 2008 10 21 32 10.1002/jgm.1122 18022932
53. T-Cell Immune Responses Against Env from CRF12-BF and Subtype B HIV-1 Show High Clade-Specificity that Can Be Overridden by Multiclade Immunizations. Monaco DC, Rodriguez AM, Pascutti MF, Mauricio C, Juliana F, Alejandro G, Cynthia M, Gabriela T, Najera JL, Mariano E, Magdalena Gherardi M, PlosOne 2011 6 17185 10.1371/journal.pone.0017185
54. GTU®-MultiHIV DNA vaccine results in protection in a novel P815 tumor challenge model. Malma M, Sikut R, Krohn K, Blazevi V, Vaccine 2007 25 3293 3301 10.1016/j.vaccine.2007.01.003 17289222 (Pubitemid 46527992)
55. IgG Subclass Profiles in Infected HIV Type 1 Controllers and Chronic Progressors and in Uninfected Recipients of Env Vaccines. Banerjee K, Klasse PJ, Rogier Sanders W, Pereyra F, Michael E, Lu M, Bruce Walker D, John Moore P, AIDS Res Hum Retroviruses 2010 26 445 458 10.1089/aid.2009.0223 20377426